Imaging Features for the Risks for Recurrence After Stereotactic Radiosurgery in Brain Metastasis

Sponsor
Asan Medical Center
Study ID
NCT05868928
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases
  • Radiosurgery

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Magnetic resonance imaging (MRI) — DIAGNOSTIC_TEST
    Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image
  • Diffusion-weighted MRI — DIAGNOSTIC_TEST
    Diffusion-weighted MRI
  • Arterial spin labeling (ASL) — DIAGNOSTIC_TEST
    Cerebral blood flow imaging parameter
  • Dynamic susceptibility contrast-MRI (DSC-MRI) — DIAGNOSTIC_TEST
    Cerebral blood volume and vessel architectural imaging parameters

Study Details

This trial uses multi-parametric magnetic resonance imaging (MRI) to develop and validate imaging risk score to predict radiation necrosis in participants with brain metastasis treated with radiation therapy. Diagnostic procedures, such as multi-parametric magnetic resonance imaging (MRI), may improve the ability to diagnose radiation necrosis early and help establish treatment strategies.

Key Dates

First listed
May 22, 2023
Start date
Dec 7, 2023
Status verified
May 2024
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026

Study Design

Enrollment
132 participants (estimated)

Arms

  • Arm: Brain metastases patients who received stereotactic radiosurgery
    Patients with brain metastases who received stereotactic radiosurgery

Primary Outcome Measure

Time to progression [ Time Frame: up to 24 months ]

Central Contacts

Related Studies